Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder

IRVINE, Calif. & BASEL, Switzerland–(BUSINESS WIRE)–Urovant Sciences (Nasdaq: UROV), a clinical-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for urologic conditions, today announced it will
host a conference call and live webcast to discuss topline results from
the EMPOWUR international pivotal phase 3 study on Tuesday, March 19,
2019 at 8:30 a.m. ET. A question and answer session will follow
management’s remarks.

The conference call numbers are (866) 470-1049 for domestic callers and
+1 (409) 217-8245 for international callers. The conference ID is
9455883. The webcast link to view the presentation is available at: https://edge.media-server.com/m6/p/oey7muvz.

A replay of the call will be available approximately four hours after
the call and accessible for 30 days at (855) 859-2056 for domestic
callers and +1 (404)-537-3406 for international callers. The conference
ID is 9455883. A webca